Study met primary endpoint of ≥15-letter (≥3-line) gain in mesopic low contrast distance visual acuity in comparison to placebo Phase 3 study showed patient-reported functional benefit in treating significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision, a condition with no current FDA-approved therapies Safety profile consistent… Read More..

FT. LAUDERDALE, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- EdgeMode Inc. (OTC: EDGM), today announced the successful acquisition of Synthesis Analytics Production Ltd. (SAPL), a strategic step in the company’s expansion into the high-performance computing AI-focused data center market. The acquisition which closed on April 7, 2025, provides EdgeMode with… Read More..

Reaffirming Commitment to Innovation, Industry Leadership, and Shareholder Value SOUTH ORANGE, NJ - May 28, 2025 (NEWMEDIAWIRE) - Nephros, Inc.(Nasdaq: NEPH), a leading water technology company providing high-performance filtration solutions to the medical and commercial markets, today announced that they will host an upcoming Analyst and Investor Virtual Event. Robert… Read More..